Calgary, AB – TheNewswire - June 7, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, advises that it has closed its previously announced (see News Release of April 12) non-brokered private placement offering of common shares (the “Offering”) and has issued a total of 13,500,000 [...]

Calgary, AB – TheNewswire - April 29, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, is pleased to provide an update on its planned Clinical Trial Application (“CTA”) process.  UI has engaged a new clinical research organization (“CRO”) to complete the process of compiling UI’s [...]

Calgary, AB – TheNewswire - April 22, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, advises that it intends to undertake a non-brokered private placement offering of up to 23,333,333 common shares at a price of $0.015 per share, for proceeds of up to $350,000 [...]

Calgary, AB – TheNewswire - April 12, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, advises that it intends to undertake a non-brokered private placement offering of up to 30,000,000 common shares at a price of $0.02 per share, for proceeds of up to $600,000 [...]

Calgary, AB – TheNewswire - April 10, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, is pleased to announce that it has closed its previously announced (see News Release of February 22) non-brokered private placement offering of common shares (the “Offering”) and has issued 57,557,600 [...]

Calgary, AB – TheNewswire - April 8, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, advises that Ian Rabb, Chief Clinics Officer, is no longer with the Company.  Mr. Rabb’s role with the Company’s subsidiary, which operates the Kelburn Recovery Centre (“Kelburn”) addiction treatment facility [...]

Calgary, AB – February 22, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, advises that it is undertaking a private placement offering of up to 80,000,000 common shares at a price of $0.01 per share (the “Offering”) for proceeds of up to $800,000. The proceeds [...]

Calgary, AB – February 7, 2023 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, is pleased to announce the closing of its previously announced (see news release of December 20, 2023) non-brokered private placement (the “Placement”) of common shares, and has issued 41,719,250 common shares at [...]

Calgary, AB – February 2, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, provides the following bi-weekly default status report update: Further to the Company’s prior news release (January 19, 2024), the Company is providing this bi-weekly default status report (the “Default Status Report”) in [...]

Calgary, AB – TheNewswire - January 19, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, provides the following bi-weekly default status report update: Further to the Company’s prior news release (January 5, 2024), the Company is providing this bi-weekly default status report (the “Default Status Report”) in accordance with National Policy 12‑203 Management Cease Trade Orders (“NP 12-203”). On November 20, 2023, UI announced that it would delay the filing of its annual audited financial statements for the [...]